Sartorius simplifies biologics production with new bioreactor
BIOSTAT STR Generation 3, 2000 L.
Company launches BIOSTAT STR Generation 3 bioreactor with BIOBRAIN automation platform.
Engineered to address the rigorous requirements and complexity of biologics manufacture, Sartorius now offers its BIOSTAT STR Generation 3 single-use bioreactor and BIOBRAIN automation platform to change biopharmaceutical process development and manufacturing.
BIOSTAT STR is a robust industrial platform consisting of hardware, software and consumables for single-use process development and commercial biomanufacturing. This generation of bioreactors and Flexsafe STR bags range from 12.5 L to 2000 L in working volume.
The system is powered by BIOBRAIN, a new automation platform that gives biologics manufacturers the flexibility to quickly and easily configure the BIOSTAT STR system to meet their precise needs. Data-driven software, a comprehensive suite of analytical tools and experienced engineering design and support teams enable manufacturers to produce consistent results, even in the setting of changing demands.
Fully integrated and redundant single-use sensors provide real-time data to measure and control key critical process parameters such as pH, DO, viable biomass, glucose, lactate and foam. Non-invasive measurements save set-up time, prevent interface issues and reduce the need for off-line manual sampling. These monitoring and control systems enhance batch-to-batch consistency and operator confidence.
BIOSTAT STR Generation 3 is ready for process intensification and includes functionalities such as feed controls, bleed controls and connectivity to Repligen’s XCell ATF cell retention devices to increase cell density and productivity.
Connection to Umetrics SIMCA enables predictive, multivariate modeling and control, allowing manufacturers to predict yield and optimal harvest time points at the early stages of the perfusion process.
Integration into existing process infrastructure can be achieved in multiple ways: local management via the BIOSTAT STR control tower and BIOBRAIN automation platform with connection to data histories, or full process management via distributed control systems from Emerson, Siemens or Rockwell. An additional feature for BIOSTAT STR Generation 3 is the optional integration of native Emerson DeltaV controls supported by a Sartorius DeltaV library, which affords full access and control from DeltaV systems.
Sartorius engineering and technical field experts help design and implement new facilities and retrofits, address scaling challenges and manage technology transfers. This level of support relieves internal development and manufacturing teams from the burden of developing master status on new technology.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...